Kim et al. showed a strong correlation between the mutations in TP53, Lysine Methyltransferase 2D (KMT2D), and TET2 during TKI therapy and treatment failure in CML patients [82]. This evidence concerns the gene TET2 and chronic myelogenous leukemia, BCR-ABL1 positive.